Literature DB >> 6610686

Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting.

D M Slovik, C M Gundberg, R M Neer, J B Lian.   

Abstract

Serum levels of osteocalcin, the major noncollagenous bone protein, are elevated in patients with certain metabolic bone diseases, but the effects of other illnesses on serum osteocalcin levels are not known. We measured serum osteocalcin concentrations in 250 patients in a rehabilitation hospital who suffered from various illnesses. Mean serum osteocalcin levels were elevated in patients with 1) recent hip fracture who required open reduction and pin insertion (mean +/- SE, 19.0 +/- 3.2 ng/ml), 2) primary (22.0 +/- 4.9 ng/ml) or secondary hyperparathyroidism (51.6 +/- 9.9 ng/ml), 3) Paget's disease of bone (22.7 +/- 6.1 ng/ml), or 4) metastatic skeletal disease who had not received therapy (37.5 +/- 11.3). Mean serum osteocalcin levels were normal in patients who had received 1) a hip prosthesis for a recent fracture or for severe degenerative joint disease of the hip (6.4 +/- 0.9 ng/ml), 2) recent chemotherapy or irradiation for bone metastases (6.1 +/- 1.3 ng/ml), or 3) a variety of medical problems not related to bone disease (5.2 +/- 0.3 ng/ml). Serum osteocalcin and alkaline phosphatase values did not correlate. This study demonstrates that serum osteocalcin levels are normal in disorders not involving bone, can be used in a general-hospital setting, where concomitant illnesses are present, and may provide additional information for the clinical evaluation of metabolic bone disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610686     DOI: 10.1210/jcem-59-2-228

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

Review 1.  Diagnostic biomarkers for oral and periodontal diseases.

Authors:  Mario Taba; Janet Kinney; Amy S Kim; William V Giannobile
Journal:  Dent Clin North Am       Date:  2005-07

2.  The effect of high-dose salmon calcitonin on bone mineral metabolism in the normal rat.

Authors:  N Glajchen; S Thomas; P Jowell; S Epstein; F Ismail; M Fallon
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

3.  The value of biomarkers in detecting alterations in bone metabolism.

Authors:  M Azria
Journal:  Calcif Tissue Int       Date:  1989-07       Impact factor: 4.333

4.  Multiple immunoreactive forms of osteocalcin in uremic serum.

Authors:  C M Gundberg; R S Weinstein
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

5.  Differences in basal and postexercise osteocalcin levels in athletic and nonathletic humans.

Authors:  S Nishiyama; S Tomoeda; T Ohta; A Higuchi; I Matsuda
Journal:  Calcif Tissue Int       Date:  1988-09       Impact factor: 4.333

6.  Postoophorectomy bone loss is associated with reduced bone Gla protein serum levels: a possible effect of osteoblastic insufficiency.

Authors:  C E Fiore; E Falcidia; R Foti; S Caschetto; D R Grimaldi
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

7.  Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort.

Authors:  C Montecucco; F Baldi; A Fortina; G Tomassini; R Caporali; E L Cherie-Ligniere; P Fratino
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

8.  Indicators of bone formation in weight lifters.

Authors:  M K Karlsson; P Vergnaud; P D Delmas; K J Obrant
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

9.  Serum bone Gla protein as a marker of bone turnover in acromegaly.

Authors:  M Marazuela; B Astigarraga; M J Tabuenca; J Estrada; F Marín; T Lucas
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

10.  Biochemical short-term changes produced by hormonal replacement therapy.

Authors:  J F Aloia; A Vaswani; J K Yeh; D M McGowan; P Ross
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.